Renal clearable polyfluorophore nanosensors for early diagnosis of cancer and allograft rejection

Optical nanoparticles are promising diagnostic tools; however, their shallow optical imaging depth and slow clearance from the body have impeded their use for in vivo disease detection. To address these limitations, we develop activatable polyfluorophore nanosensors with biomarker-triggered nanoparticle-to-molecule pharmacokinetic conversion and near-infrared fluorogenic turn-on response. Activatable polyfluorophore nanosensors can accumulate at the disease site and react with disease-associated proteases to undergo in situ enzyme-catalysed depolymerization. This disease-specific interaction liberates renal-clearable fluorogenic fragments from activatable polyfluorophore nanosensors for non-invasive longitudinal urinalysis and outperforms the gold standard blood and urine assays, providing a level of sensitivity and specificity comparable to those of invasive biopsy and flow cytometry analysis. In rodent models, activatable polyfluorophore nanosensors enable ultrasensitive detection of tumours (1.6 mm diameter) and early diagnosis of acute liver allograft rejection. We anticipate that our modular nanosensor platform may be applied for early diagnosis of a range of diseases via a simple urine test. Early cancer detection typically involves invasive biopsies. Here the authors designed nanosensors that are depolymerized by disease-associated enzymes in vivo to produce fluorescent urinary signals for non-invasive early diagnosis.

Automated summary

This study develops activatable polyfluorophore nanosensors that can react with disease-associated proteases to produce fluorescent signals for non-invasive disease diagnosis. These nanosensors show promising results in detecting tumors and diagnosing acute liver allograft rejection in rodent models.